It was paired with USD 189.15 million in 2016 and is expected to grow at a CAGR of 6% over the forecast period. The market is driven primarily by the increasing prevalence of diseases such as benign prostatic hypertrophy, bladder cancer, neurogenic bladder dysfunction, overactive bladder, etc. (Get 15% Discount on Buying this Report) […]
